Fusion Protein Technologies for Biopharmaceuticals
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN
Fusion proteins belong to the most lucrative biotech drugswith Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the ...
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN
Fusion proteins belong to the most lucrative biotech drugswith Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the ...